Michael Giitter, MD
Internal Medicine · Omaha, NENPI 1851406524
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 298 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 298 payments — averaging $15.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$710
- Lilly USA, LLC$662
- Novo Nordisk$525
- Otsuka America Pharmaceutical, Inc.$311
- Amgen$298
- Boehringer Ingelheim$295
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,40499%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 55 | $710 |
| Lilly USA, LLC | 62 | $662 |
| Novo Nordisk | 32 | $525 |
| Otsuka America Pharmaceutical, Inc. | 17 | $311 |
| Amgen | 19 | $298 |
| Boehringer Ingelheim | 17 | $295 |
| AbbVie | 15 | $263 |
| Astellas Pharma US Inc | 9 | $149 |
| Bayer | 9 | $135 |
| Boston Scientific | 4 | $124 |
| Merck | 6 | $90 |
| Sanofi-aventis U.S. LLC | 4 | $74 |
| AstraZeneca | 5 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $70 |
| Gilead | 3 | $64 |
| Exact Sciences | 3 | $60 |
| Corcept Therapeutics | 3 | $53 |
| Abbott | 3 | $52 |
| Xeris Pharmaceuticals, Inc. | 3 | $52 |
| Novartis | 3 | $45 |
| Actelion Pharmaceuticals US, Inc. | 2 | $43 |
| Avanir Pharmaceuticals, Inc. | 3 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Sumitomo Pharma America, Inc. | 2 | $30 |
| Pulmonx Corporation | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Bausch Health US, LLC | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| GSK | 1 | $11 |
| Phathom Pharmaceuticals, Inc. | 1 | $7 |
How this compares
$4,469 in reported general payments places this provider in the 90th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 248 | $176,373 |
| JardianceEmpagliflozin | 177 | $164,335 |
| OzempicSemaglutide | 61 | $61,440 |
| RybelsusSemaglutide | 38 | $45,435 |
| JanuviaSitagliptin Phosphate | 29 | $35,532 |
| MyrbetriqMirabegron | 44 | $28,333 |
| XareltoRivaroxaban | 13 | $18,912 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $15,458 |
| TrulicityDulaglutide | 12 | $11,897 |
| Atorvastatin Calcium | 1,263 | $8,318 |
| RestasisCyclosporine | 20 | $6,871 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $6,622 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,414 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,910 |
| Levothyroxine Sodium | 596 | $4,865 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $710 | $176,373248 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $295 | $170,748189 claims |
| Novo NordiskOzempic, Rybelsus | $525 | $106,87599 claims |
| MerckJanuvia | $90 | $35,53229 claims |
| Astellas Pharma US IncMyrbetriq | $149 | $28,33344 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta | $11 | $14,92736 claims |
| Lilly USA, LLCTrulicity | $662 | $11,89712 claims |
| AbbVieRestasis, Synthroid | $263 | $9,72253 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 570 internal medicine providers in Nebraska.
Other internal medicine in Omaha
- Brian BoerOmaha$142K
- Adam BurdorfOmaha$29K
- David SharpOmaha$26K
- David ShinOmaha$26K
- Nikhil JaganOmaha$20K
- Clayton SchroederOmaha$14K
- Ali NayfehOmaha$12K
- Kirtibala GuptaOmaha$12K
- Chad VokounOmaha$11K
- Joel MichalskiOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.